Low Dose Aspirin

Phase 3Small molecule

MMayo Clinic

Low Dose Aspirin is one of 71 small molecule programs targeting Congestive Heart Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congestive Heart FailureActive, not recruiting

Multiple SclerosisActive, not recruiting

Congestive Heart FailurePhase 1

Active, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Low Dose Aspirin

MMayo Clinic

Phase 3

1 4

Campath

GGenzyme, a Sanofi Company

Preclinical

12 5

Zinbryta

Roche

Preclinical

2 6

Flomax

Sanofi

Preclinical

1 7

Pred Forte

Myfortic

Novantrone

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congestive Heart Failure1 trial

Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

Terminated·MMayo Clinic·Phase 1·NCT00818701·1 enrolled

Hospitalized Patients1 trial

The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies

Terminated·MMayo Clinic·N/A·NCT01978509·32 enrolled

Renal Replacement Therapy1 trial

High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy

Withdrawn·MMayo Clinic·Phase 4·NCT03846258

Multiple Sclerosis1 trial

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

Terminated·MMayo Clinic·Phase 3·NCT00467584·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Low Dose Aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low Dose Aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low Dose Aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Low Dose Aspirin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congestive Heart Failure1 trial

Hospitalized Patients1 trial

Renal Replacement Therapy1 trial

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News